The Phase III portion of the companies' trial of Kevzara will now only enroll critically ill patients and randomize them to receive the drug at 400mg or placebo, after the drug did not appear effective in severely ill patients.
An official form Northwell Health said trials of Gilead and Regeneron drugs were able to get up and running in four days rather than taking months to start, in part because clinical trials in other disease areas have been put on hold.
A new independent study from Phyx Primary Care’s Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices.
With a list price 30% lower than the top TNF-alpha inhibitors, Regeneron and Sanofi's Kevzara could make waves in the blockbuster rheumatoid arthritis market.